Loading
Loading
Research Overview
Szeto-Schiller tetrapeptide that selectively targets the inner mitochondrial membrane by binding cardiolipin; reduces mitochondrial reactive oxygen species, preserves the mitochondrial cristae structure, and restores ATP synthesis efficiency under conditions of oxidative stress.
SS-31 is a cell-permeable tetrapeptide with the sequence D-Arg-2′6′-Dmt-Lys-Phe-NH2 that selectively concentrates at the inner mitochondrial membrane through electrostatic interaction with cardiolipin. Cardiolipin is a unique phospholipid essential for the structural integrity of mitochondrial cristae, the optimal function of the electron transport chain, and the regulation of cellular apoptosis. By binding cardiolipin, SS-31 has been studied in preclinical models for its ability to stabilise mitochondrial membrane architecture and reduce electron transport chain-derived reactive oxygen species production.
In preclinical cardiac research, SS-31 has been extensively studied in models of ischaemia-reperfusion injury, heart failure, and myocardial infarction. Laboratory studies have examined how mitochondrial membrane stabilisation by SS-31 influences cardiomyocyte survival, oxidative damage, and functional recovery following experimentally induced cardiac ischaemia. Animal model data have characterised the compound's pharmacokinetic profile in cardiac tissue and its effects on mitochondrial structure and function in the post-ischaemic myocardium.
Beyond cardiac biology, SS-31 has been studied in preclinical models of neurodegenerative disease, renal injury, skeletal muscle atrophy, and metabolic dysfunction. These diverse research applications reflect the fundamental importance of mitochondrial function across tissue types and the relevance of cardiolipin-targeted approaches for studying mitochondrial biology in laboratory settings.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, ss-31 (elamipretide) mitochondria-targeted peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
SS-31 (Elamipretide) Mitochondria-Targeted Peptide research is most relevant to protocols examining:
Mitochondrial dysfunction and oxidative stress research
Cardiac ischaemia-reperfusion injury studies
Heart failure and cardiomyopathy research
Cardiolipin biology and mitochondrial cristae preservation investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Szeto-Schiller tetrapeptide that selectively targets the inner mitochondrial membrane by binding cardiolipin; reduces mitochondrial reactive oxygen species, preserves the mitochondrial cristae structure, and restores ATP synthesis efficiency under conditions of oxidative stress.
| Parameter | Value |
|---|---|
| Dose range | 0.05–0.25 mg/kg/day (trial doses) |
| Schedule | Daily |
| Route | Subcutaneous, Intravenous |
| Half-life | ~Hours |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
